Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mucormycosis is an invasive, life-threatening fungal infection that mainly affects immunocompromised hosts. We collected data of pediatric mucormycosis cases from all 7 Greek Hematology-Oncology Departments for the years 2008-2017. Six cases of invasive mucormycosis diagnosed during treatment for malignancies were included in the study. In 4 children (66%) mucormycosis occurred within the first 20 days after diagnosis of the underlying disease. Two cases were classified as proven mucormycosis and 4 as probable. The most frequently recorded species was Rhizopus arrhizus (2 patients), followed by Mucor spp (1), and Lichtheimia spp (1). All patients received liposomal amphotericin B. Combined antifungal treatment was used in 5 cases. Surgical excision was performed in 4 cases (66%). Two patients died at 6 and 12 months after the diagnosis, respectively, 1 (17%) because of mucormycosis. Our data suggest that mucormycosis may occur early after the initiation of intensive chemotherapy in children with malignancies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000001931 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aspergillosis and Mucormycosis-Associated Hospitalizations, United States, 2016-2021.
Mycoses
September 2025
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Background: In the United States, aspergillosis and mucormycosis are associated with substantial healthcare costs and mortality. Recent nationally representative data about hospitalisations for these infections are limited, though several reports specifically describe increases in COVID-19-associated aspergillosis and mucormycosis, likely because of critical illness-related immune dysregulation and treatments involving systemic corticosteroids.
Objectives: To update disease burden estimates, we describe trends in aspergillosis-related and mucormycosis-related hospitalisations (A-RH and M-RH).
Automated Mucormycosis Diagnosis from Paranasal CT Using ResNet50 and ConvNeXt Small.
Bioengineering (Basel)
August 2025
Department of Otorhinolaryngology and Head and Neck Surgery Clinic, Faculty of Medicine, Dicle University, Diyarbakir 21010, Turkey.
Purpose: Mucormycosis is a life-threatening fungal infection, where rapid diagnosis is critical. We developed a deep learning approach using paranasal computed tomography (CT) images to test whether mucormycosis can be detected automatically, potentially aiding or expediting the diagnostic process that traditionally relies on biopsy.
Methods: In this retrospective study, 794 CT images (from patients with mucormycosis, nasal polyps, or normal findings) were analyzed.
Rhinosinusitis in Advanced HIV: A Rare and Lethal Mucormycosis.
Case Rep Pathol
August 2025
Department of Internal Medicine, University of the Free State Faculty of Health Sciences, Bloemfontein, South Africa.
Mucormycosis is a severe invasive infection caused by the Mucorales fungi. The most frequently implicated genera are species, species, and species. These fungi do not typically cause infections in immunocompetent individuals.
View Article and Find Full Text PDF[Clinical characteristics and outcomes of invasive mucormycosis after allogeneic hematopoietic stem cell transplantation].
Zhonghua Yi Xue Za Zhi
August 2025
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
To explore the clinical characteristics and prognostic factors of patients with invasive mucormycosis (IM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical data of IM patients after allo-HSCT in Peking University People's Hospital from January 1, 2010 to December 31, 2021 were retrospectively collected and followed up until October 1, 2022. The survival curve was plotted by the Kaplan-Meier method.
View Article and Find Full Text PDFPulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka.
Cureus
July 2025
Department of Pulmonary Medicine, National Hospital for Respiratory Diseases, Welisara, LKA.
Pulmonary mucormycosis is a rare but aggressive fungal infection that primarily affects immunocompromised individuals, especially those with uncontrolled diabetes mellitus. Its non-specific presentation can mimic more common pulmonary conditions, often resulting in delayed diagnosis and treatment. Here, we present a case series of three Sri Lankan patients with type 2 diabetes mellitus who developed pulmonary mucormycosis.
View Article and Find Full Text PDF